Travere Therapeutics, Inc.
TVTX · Price history
Price at last available close
$50.84
−$10.73 (-17.42%) 1M
2026-10-28
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About Travere Therapeutics, Inc.
Primary reporting period: 2025-12-31 · Research updated Oct 12, 2026. A research update is not a new financial filing.
Who they are
Travere Therapeutics, Inc. is a biopharmaceutical company developing therapies for rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral, once-daily, non-immunosuppressive medication targeting two pathways of disease progression (endothelin-1 and angiotensin-II). Sparsentan received accelerated FDA approval in February 2023 and full approval in September 2024 to slow kidney function decline in adults with primary IgA nephropathy (IgAN) at risk of progression.
How they make money
Travere Therapeutics is a biopharmaceutical company that generates revenue primarily through the commercialization of its proprietary therapeutic products, such as FILSPARI, for the treatment of rare kidney diseases. The company also enters into licensing and collaboration agreements with other pharmaceutical entities, receiving upfront payments, milestone payments, and potential future royalties for the development and commercialization of its drug candidates in specific geographic territories.
Products & services
The company's primary commercial product is FILSPARI (sparsentan), a medication indicated for the treatment of certain rare kidney diseases, including IgA nephropathy.
Brands & revenue mix
The company's primary commercial product for the treatment of IgA nephropathy.
Separate brand revenue is not available in this research.Source
Revenue share is not unit sales or a best-seller ranking. Parent brands and included sub-brands can overlap; do not add overlapping rows.
Product / operating segments
Geographic revenue
No reconciled geographic revenue breakdown was confirmed for the current research period.
Customer concentration
The company's revenue is primarily derived from specialty pharmacy distributors and wholesalers, which creates a concentration of customers in the distribution channel as of 2025-12-31.
Suppliers, materials & equipment
- Contract Manufacturing Organizations — The company relies on third-party contract manufacturing organizations for the production of its drug products; specific supplier names are unnamed.Source
Business relationships & partnerships
- CSL Vifor — A licensing agreement under which CSL Vifor commercializes FILSPARI in certain international territories, with Travere receiving milestone payments.Source
- Renalys Pharma — A licensing agreement for the development, regulatory matters, and commercialization of sparsentan in specific licensed territories.Source
- Chugai Pharmaceutical — A collaboration for the development and regulatory approval of sparsentan in Japan.Source
Strengths
Financial risk observations and what to check
These are saved observations about business performance, not predictions. Review the company filings alongside the interpretation below. Latest stored financial period end: 2026-06-30.
Total debt increased 54.4% versus the same quarter last year.
Compare the added borrowing with available cash, cash generation and maturities. A percentage increase from a small starting balance can look large without measuring the full debt burden.
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
22
Poor
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
35
Poor
Financial Strength
34
Business Quality / Moat
58
Management
0
Growth Quality
65
Risk / Durability
10
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Opportunity
Opportunity Score · How does the current price compare with estimated value?
42
Avoid
Based on current valuation, company quality, recent trends, and available market signals.
View score details →
Model Outlook
12-month model · What does the model think happens next?
54/100
Building Historical Record
Model Score 54/100 — estimates relative performance potential, distinct from the overall Wall Street Score and the separate Company Quality score.
Probability unavailable — the model has not produced a calibrated probability yet.
Click for full breakdown →
WSS View
The quick read
The overall Wall Street Score is low across its combined quality, valuation and risk inputs. This can reflect an expensive share price, business weaknesses, or both; check Company Quality and the category breakdown before drawing a conclusion.
At today’s price, the WSS valuation framework currently reads as less attractive based on the available valuation and market data.
The model outlook is currently moderate.
No strong positive signal is being highlighted from the currently available summary data.
- •Elevated debt risk
- •Valuation is a weaker part of the current profile
- •Revenue fundamentals are weak
- •Asset quality is a weaker factor
Company-specific research
Questions worth answering for TVTX
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •Can TVTX maintain its current revenue growth rate and improve the amount of that revenue that turns into earnings and cash?
- •How long can TVTX fund negative free cash flow using its current cash position before it may need more debt or new shares?
- •Is TVTX's debt load manageable relative to cash generation, interest costs and upcoming maturities?
- •What specifically needs to improve for TVTX to reach sustainable profitability?
- •What future growth or profitability would be needed to justify TVTX's current valuation?
Essential Investment Snapshot
Wall Street Score
22
Opportunity Score
42
Market Cap
$4.79B
P/E Ratio
-125.7
EPS
$-0.45
52-Week High
$68.73
52-Week Low
$22.59
Beta
1.06
Analyst Target
$70.00
Shares Outstanding
89.2M
Total Revenue
$591.3M
Total Debt
$616.9M
Dividend
No current dividend
Liquidation Value / Share
$0.27
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Strong downward momentum
Low movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for TVTX
Detected from reported data — verify before acting.Elevated debt risk
Interest coverage is below 2x • Free cash flow is negative • Cash covers less than 20% of total debt
Community Sentiment
0 active · 0 total callsNo personal call yet on TVTX.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Fully integrated biopharmaceutical capabilities.
- +Focus on rare kidney and metabolic diseases.
Potential downside factors
- −Debt risk (elevated): Interest coverage is below 2x.
- −Free cash flow is negative.
- −Cash covers less than 20% of total debt.
- −Dependence on third-party manufacturers.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
2 historical score records availablePrevious Score
24
Jul 24, 2026
Change
-1.9
points
Current Score
22
Oct 1, 2026
Category Changes
TVTX decreased 1.9 points because Debt declined by 27.2 points, Buffett declined by 5.3 points.
Positive Contributors
- + Revenue improved by 7.7 points
Negative Contributors
- − Debt declined by 27.2 points
- − Buffett declined by 5.3 points
Projected Score
Projected Score
28
Projected Change
+5.6 points
Preliminary comparable-period financial changes suggest improvement of approximately 5.6 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
Valuation unavailableCurrent Price
$50.84
Model Intrinsic Value
—
Difference
—
Margin of Safety
—
Intrinsic value is not currently available for this stock, so valuation can't be calculated.
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Large reported revenue change: +110.5%
Revenue changed sharply from 2024 to 2025. This can reflect a real business change, acquisition, divestiture, discontinued operations, restatement, or reporting-basis change. Compare the underlying filing before treating it as normal growth or decline.
TTM may combine quarters from before and after the event, so its trend can also be distorted.
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $591.3M | $490.7M | $233.2M | $145.2M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Cost of Revenue | $33.1M | $10.3M | $7.7M | $11.4M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Gross Profit | $558.3M | $480.4M | $225.4M | $133.8M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Research & Development | $227.1M | $206.0M | $282.7M | $245.0M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| SG&A Expenses | $364.5M | $337.2M | $264.1M | $265.5M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Expenses | $598.7M | $543.2M | $549.3M | $521.9M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| EBITDA | $1.5M | $22.2M | -$265.8M | -$326.2M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Income | -$40.5M | -$62.8M | -$323.8M | -$388.1M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Interest Expense | $9.5M | $10.7M | $11.2M | $11.3M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Before Tax | -$67.1M | -$49.3M | -$320.5M | -$376.1M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Tax Expense | $605K | $988K | $120K | $223K | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Net Income | -$43.5M | -$25.5M | -$321.5M | -$111.4M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic EPS | $-0.72 | $-0.56 | $-4.08 | $-1.50 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic Shares | 93.48M | 89.21M | 78.89M | 74.27M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Diluted Shares | 93.48M | 89.21M | 78.89M | 74.27M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
Earnings Summary
Revenue
$169.6M
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
-$0.37
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
+54.4%
Cash Change
+56.7%
Margin Change
-9.4 pp
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Improved
- Cash position grew
What Weakened
- Margins contracted
- Debt increased
Potential Score Impact
Positive indicators included revenue growth, EPS growth, cash levels. Pressure indicators included debt levels, net income margin. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
Revenue increased 48.2%. EPS increased 164.3%. Cash increased 56.7%. Total debt increased 54.4%. Net income margin declined by 9.4 percentage points.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
47
Smart Money
47
Number of Gurus
2
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
2 historical records2 historical score records available.
Historical Score Chart
2 of 2 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
BiotechnologyNews
Travere Presents New Biomarker Data at ASN Kidney Week Suggesting FILSPARI® (sparsentan) May Modify Underlying Disease Pathophysiology in IgA Nephropathy
Earnings Preview: Travere Therapeutics (TVTX) Q3 Earnings Expected to Decline
Travere to Present New Data Supporting FILSPARI® (sparsentan) as Foundational Treatment in IgA Nephropathy and FSGS at ASN Kidney Week 2026
Kuehn Law Encourages Investors of Travere Therapeutics, Inc. to Contact Law Firm
Rumor Mill · TVTX
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial